TY - JOUR
T1 - Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under
T2 - Addressing the Unknowns and Rationale for a Multicenter Clinical Trial
AU - Wong, Germaine
AU - Marsh, Julie
AU - Howell, Martin
AU - Lim, Wai H.
AU - Chadban, Steve
AU - Coates, Toby
AU - Hawley, Carmel
AU - Campbell, Scott
AU - Larkins, Nicholas
AU - Snelling, Tom
AU - Allan, Lachlan
AU - Teixeira-Pinto, Armando
AU - Reidlinger, Donna
AU - Wyburn, Kate
AU - Craig, Jonathan C.
N1 - This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PY - 2020/10
Y1 - 2020/10
N2 - BK polyomavirus infection in transplanted kidneys that leads to BK virus–associated nephropathy (BKVAN) is an important cause of allograft loss and has limited treatment options.1 Recent data suggest that BK viremia affects approximately 10% of people within the first 12 months following kidney transplantation.2 Among recipients with BKVAN, the overall risk of allograft loss is substantially increased, estimated to be 50% within 5 years of diagnosis. Geographic variation in the rates of BK infection also has been recognized. Depending on local epidemiology and immunosuppression practices, the prevalence of viruria, viremia, and histological features of BKVAN is reported to be between 35% and 40%, 12% and 15%, and 3% and 8%, respectively.3
AB - BK polyomavirus infection in transplanted kidneys that leads to BK virus–associated nephropathy (BKVAN) is an important cause of allograft loss and has limited treatment options.1 Recent data suggest that BK viremia affects approximately 10% of people within the first 12 months following kidney transplantation.2 Among recipients with BKVAN, the overall risk of allograft loss is substantially increased, estimated to be 50% within 5 years of diagnosis. Geographic variation in the rates of BK infection also has been recognized. Depending on local epidemiology and immunosuppression practices, the prevalence of viruria, viremia, and histological features of BKVAN is reported to be between 35% and 40%, 12% and 15%, and 3% and 8%, respectively.3
UR - http://www.scopus.com/inward/record.url?scp=85091205951&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1147657
U2 - 10.1016/j.ekir.2020.06.038
DO - 10.1016/j.ekir.2020.06.038
M3 - Article
AN - SCOPUS:85091205951
SN - 2468-0249
VL - 5
SP - 1777
EP - 1780
JO - Kidney International Reports
JF - Kidney International Reports
IS - 10
ER -